In addition, other CD4+ cell types were identified, including a) CD4+ memory cells expressing CCR7, SELL, TCF7; b) CD4+ resting cells expressing ANXA1, IL7R, LMNA; c) CXCL13 activated CD4+ cells (Fig. 5A, B, Additional file 9: Table S8) which have been linked to better outcomes in MSI CRC, bladder, and stomach malignancies [50–52], but were also identified in normal tissue (perhaps attributable to sequencing issues); and d) Th17 CD4+ T cells that represent critical antitumor effector cells [51]. This evidence concerns the gene CXCL13 and colorectal carcinoma.